ONC PE Ratio & Valuation,Is ONC Overvalued — Intellectia
ONC Relative Valuation
ONC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ONC is overvalued; if below, it's undervalued.
Historical Valuation
BeOne Medicines AG(ONC) is now in theFairzone, suggesting that its currentforward PEratio of68.52is consideredFairlycompared with the five-year average of79.97.The fair price ofBeOne Medicines AG(ONC)is between36.58to587.04according to relative valuation methord.
Relative Value
Fair Zone
36.58-587.04
Current Price：310.67
Fair
68.52
PE
1Y
3Y
5Y
Trailing
Forward
41.25
EV/EBITDA
BeOne Medicines AG. (ONC) has a current EV/EBITDA of 41.25. The 5-year average EV/EBITDA is 24.52. The thresholds are as follows: Strongly Undervalued below -60.28, Undervalued between -60.28 and -17.88, Fairly Valued between 66.92 and -17.88, Overvalued between 66.92 and 109.33, and Strongly Overvalued above 109.33. The current Forward EV/EBITDA of 41.25 falls within the Historic Trend Line -Fairly Valued range.
56.73
EV/EBIT
BeOne Medicines AG. (ONC) has a current EV/EBIT of 56.73. The 5-year average EV/EBIT is 43.30. The thresholds are as follows: Strongly Undervalued below -75.38, Undervalued between -75.38 and -16.04, Fairly Valued between 102.64 and -16.04, Overvalued between 102.64 and 161.99, and Strongly Overvalued above 161.99. The current Forward EV/EBIT of 56.73 falls within the Historic Trend Line -Fairly Valued range.
5.83
PS
BeOne Medicines AG. (ONC) has a current PS of 5.83. The 5-year average PS is 6.08. The thresholds are as follows: Strongly Undervalued below 4.21, Undervalued between 4.21 and 5.14, Fairly Valued between 7.02 and 5.14, Overvalued between 7.02 and 7.95, and Strongly Overvalued above 7.95. The current Forward PS of 5.83 falls within the Historic Trend Line -Fairly Valued range.
24.61
P/OCF
BeOne Medicines AG. (ONC) has a current P/OCF of 24.61. The 5-year average P/OCF is 75.99. The thresholds are as follows: Strongly Undervalued below -186.28, Undervalued between -186.28 and -55.15, Fairly Valued between 207.12 and -55.15, Overvalued between 207.12 and 338.25, and Strongly Overvalued above 338.25. The current Forward P/OCF of 24.61 falls within the Historic Trend Line -Fairly Valued range.
50.86
P/FCF
BeOne Medicines AG. (ONC) has a current P/FCF of 50.86. The 5-year average P/FCF is 35.79. The thresholds are as follows: Strongly Undervalued below -231.78, Undervalued between -231.78 and -98.00, Fairly Valued between 169.58 and -98.00, Overvalued between 169.58 and 303.36, and Strongly Overvalued above 303.36. The current Forward P/FCF of 50.86 falls within the Historic Trend Line -Fairly Valued range.
BeOne Medicines AG (ONC) has a current Price-to-Book (P/B) ratio of 8.33. Compared to its 3-year average P/B ratio of 5.66 , the current P/B ratio is approximately 47.09% higher. Relative to its 5-year average P/B ratio of 5.66, the current P/B ratio is about 47.09% higher. BeOne Medicines AG (ONC) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -0.94%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -0.94% , the current FCF yield is about -100.00% lower.
8.33
P/B
Median3y
5.66
Median5y
5.66
1.54
FCF Yield
Median3y
-0.94
Median5y
-0.94
Competitors Valuation Multiple
The average P/S ratio for ONC's competitors is 4.60, providing a benchmark for relative valuation. BeOne Medicines AG Corp (ONC) exhibits a P/S ratio of , which is -100% above the industry average. Given its robust revenue growth of 41.00%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ONC increased by 68.19% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 177.17 to 531.73.
The secondary factor is the Revenue Growth, contributed 41.00%to the performance.
Overall, the performance of ONC in the past 1 year is driven by P/E Change. Which is more unsustainable.
Is BeOne Medicines AG (ONC) currently overvalued or undervalued?
BeOne Medicines AG(ONC)is now in theFairzone, suggesting that its currentforward PEratio of 68.52is consideredFairlycompared with the five-year average of79.97.The fair price of BeOne Medicines AG(ONC)is between36.58to587.04according to relative valuation methord.
What is BeOne Medicines AG (ONC) fair value?
ONC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of BeOne Medicines AG (ONC) is between 36.58to587.04 according to relative valuation methord.
How does ONC's valuation metrics compare to the industry average?
The average P/S ratio for ONC's competitors is 4.60, providing a benchmark for relative valuation. BeOne Medicines AG Corp (ONC) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 41.00%, this premium appears sustainable.
What is the current P/B ratio for BeOne Medicines AG (ONC) as of Dec 16 2025?
As of Dec 16 2025, BeOne Medicines AG (ONC) has a P/B ratio of 8.33. This indicates that the market values ONC at 8.33 times its book value.
What is the current FCF Yield for BeOne Medicines AG (ONC) as of Dec 16 2025?
As of Dec 16 2025, BeOne Medicines AG (ONC) has a FCF Yield of 0.00%. This means that for every dollar of BeOne Medicines AG’s market capitalization, the company generates 0.00 cents in free cash flow.
What is the current Forward P/E ratio for BeOne Medicines AG (ONC) as of Dec 16 2025?
As of Dec 16 2025, BeOne Medicines AG (ONC) has a Forward P/E ratio of 68.52. This means the market is willing to pay $68.52 for every dollar of BeOne Medicines AG’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for BeOne Medicines AG (ONC) as of Dec 16 2025?
As of Dec 16 2025, BeOne Medicines AG (ONC) has a Forward P/S ratio of 0.00. This means the market is valuing ONC at $0.00 for every dollar of expected revenue over the next 12 months.
